I've also wondered if it would be better to do multiple studies given what we've seen and heard:

- One to measure mortality/hospitalizations,

- One to measure pre-exposure prophylaxis,

- One to measure effects on long-covid

- One to measure cardiac, kidney, or other organ damage

I have been wondering the same.  Can our one Phase II (if successful) greenlight the above multiple distinct Phase III's?   Or does each of the above indications need there own specific Phase II?

Man I hope they get this one right!   After thinking about this ...perhaps its best that they keep this trial as simple and foolproof as possible, focusing on the lowest lying fruit and the shortest path to the "revenue" word.  Once we are "rolling in it" we'll be in a great financial position to bust open the multi-trial flood gates.  Knock on wood.  GLTA